Ezetimibe plus simvastatin yields greatest CV benefit in high-risk diabetes

PHILADELPHIA — In a subgroup analysis of the IMPROVE-IT trial, which included patients with recent ACS on statin therapy, those with diabetes benefited most from the addition of ezetimibe compared with those without diabetes.
The greater benefit observed in patients with diabetes was driven by reductions in MI and ischemic stroke, Robert P. Giugliano, MD, SM, FACC, FAHA, cardiovascular medicine specialist at Brigham and Women’s Hospital and senior investigator with the Thrombolysis in Myocardial Infarction (TIMI) Study Group, said during a presentation at the third annual Heart in

Source link

Leave a Reply!

So glad to see you sticking around!

Want to be the first one to receive the new stuff?

Enter your email address below and we'll send you the goodies straight to your inbox.

Thank You For Subscribing!

This means the world to me!

Spamming is not included! Pinky promise.